Elevance Health Inc. (ELV) Misses Q2 EPS by 23c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Elevance Health Reports Second Quarter 2025 Results
July 17, 2025 6:00 AM EDT2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date
INDIANAPOLIS--(BUSINESS WIRE)-- Elevance Health, Inc. (NYSE: ELV) reported second quarter 2025 results.
"In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve,... More
